NewAmsterdam Pharma Company N.V. Increase (Decrease) in Deferred Revenue
NewAmsterdam Pharma Company N.V. (NAMS) reported Increase (Decrease) in Deferred Revenue of -$1.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was $3.99M, a 163.52% increase year-over-year.
- NewAmsterdam Pharma Company N.V. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $0.00.
- NewAmsterdam Pharma Company N.V. increase (decrease) in deferred revenue for the quarter ending 2025-06-30 was -$3.03M.
- NewAmsterdam Pharma Company N.V. increase (decrease) in deferred revenue for the quarter ending 2025-03-31 was -$2.98M.
- NewAmsterdam Pharma Company N.V. increase (decrease) in deferred revenue for fiscal 2025 was -$2.02M.
- NewAmsterdam Pharma Company N.V. increase (decrease) in deferred revenue for fiscal 2024 was -$3.95M.
- NewAmsterdam Pharma Company N.V. increase (decrease) in deferred revenue for fiscal 2023 was -$8.71M, a 147.24% decline from fiscal 2022.
- NewAmsterdam Pharma Company N.V. increase (decrease) in deferred revenue for fiscal 2022 was $18.43M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.19M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $3.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $3.99M derived: sum of 2 quarters · filed 2026-02-18 | $957.00K derived: sum of 3 quarters · filed 2026-08-05 | -$2.02M 10-K · filed 2026-02-18 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$3.03M derived: sum of 2 quarters · filed 2026-08-05 | -$6.01M 10-Q · filed 2025-11-05 | -$4.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$3.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$6.01M 10-Q · filed 2026-08-05 | -$4.50M derived: sum of 3 quarters · filed 2026-08-05 | -$6.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$2.98M 10-Q · filed 2026-05-07 | -$1.47M derived: sum of 2 quarters · filed 2026-05-07 | -$3.25M derived: sum of 3 quarters · filed 2026-05-07 | -$5.53M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$273.00K derived: sum of 2 quarters · filed 2026-02-18 | -$2.55M derived: sum of 3 quarters · filed 2026-02-18 | -$3.95M 10-K · filed 2026-02-18 |
| 2024-09-30 | -$1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$4.07M derived: sum of 2 quarters · filed 2025-11-05 | -$5.47M 10-Q · filed 2025-11-05 | -$6.27M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | -$2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$3.68M 10-Q · filed 2025-08-06 | -$4.48M derived: sum of 3 quarters · filed 2026-02-18 | -$7.42M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | -$1.40M 10-Q · filed 2025-05-08 | -$2.20M derived: sum of 2 quarters · filed 2026-02-18 | -$5.14M derived: sum of 3 quarters · filed 2026-02-18 | -$6.86M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | -$802.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$3.74M derived: sum of 2 quarters · filed 2026-02-18 | -$5.46M derived: sum of 3 quarters · filed 2026-02-18 | -$8.71M 10-K · filed 2026-02-18 |
| 2023-09-30 | -$2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$4.66M derived: sum of 2 quarters · filed 2024-11-06 | -$7.90M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$4.96M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$3.24M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $18.43M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |